Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News


Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Zogenix Announces Conference Call and Webcast to Present First Quarter 2013 Financial Results

share with twitter share with LinkedIn share with facebook
share via e-mail
05/03/2013 | 02:40pm CEST
Conference Call Scheduled for May 9, 2013 at 4:30 pm ET

SAN DIEGO, May 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the first quarter ended March 31, 2013, after the market closes on Thursday, May 9, 2013, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial (866) 318-8616 (U.S.) or (617) 399-5135 (International); participant passcode: 65838569.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning May 9, 2013 at 6:30 p.m. ET (3:30 p.m. PT) until May 16, 2013, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 23471504. A replay of the webcast will also be accessible on the Investor Relations website for one month, through June 9, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com.

         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news
Date Title
01:20p RPC INC : Other Events, Financial Statements and Exhibits (form 8-K)
01:20p BLACKROCK THROGMORTON TRUST : Statement re Disclosure of Portfolio Holdings
01:19p MARINE PRODUCTS CORP : Results of Operations and Financial Condition (form 8-K)
01:19p ATEA : Exercise of employee share options in Atea ASA ("the Company")
01:19p BLUE HILLS BANCORP, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
01:19p GLOBAL SILICA GEL MARKET 2016-2020 : Growing Demand for Silica Gel in China - Research and Markets
01:18p ENTEGRIS : meets 3Q profit forecasts
01:18p TOP NEWS : GlaxoSmithKline Maintains Guidance As Sales Increase
01:18p EQS-REGULATORY : OJSC Surgutneftegas: Statement on renewal (extension) of permit (license) of OSJC 'Surgutneftegas' for certain activity which is material to its financial and business position
Latest news
Hot News 
8.20%KERING : shares at 15-year high as Gucci turnaround impresses
-7.33%GENEL ENERGY : warns of lower-end 2016 revenue after weak oil output
-14.00%BRAINCHIP LTD (ASX : BRN) discusses SNAP, the revolutionary technology which mimics the human brain
-4.29%TELENOR : Earnings Hit by VimpelCom Impairments
-6.29%Antofagasta 3Q Copper Output Rises; Reaffirms Fiscal Year Guidance
Most Read News
10/25 SAMSUNG ELECTRONICS : Apple's holiday surprise - big sales, not so big profits
05:17a Bumpy switch to new models hits Airbus Group's third-quarter profits
10/25 APPLE : For Apple, surprise hunger for big phones leaves money on table
03:13a TOYOTA MOTOR : to recall 5.8 million cars in Japan, China, Europe over Takata airbags
10/25 AMERICAN MANGANESE : Annual general meeting results
Most recommended articles
10/25DJNEWS HIGHLIGHTS : Top Global Markets News of the Day
10/25 DEUTSCHE BANK : Schaeuble says monetary policy has reached its limits
10/25 APPLE : Gadgets in decline as R&D shifts to software and services - study
10/24DJGold Prices Turn Lower Amid Strong Economic Data